BVF Inc. IL Makes New $17.86 Million Investment in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

BVF Inc. IL purchased a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 2,325,000 shares of the company's stock, valued at approximately $17,856,000. BVF Inc. IL owned 6.36% of iTeos Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in iTeos Therapeutics by 1.2% during the third quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company's stock worth $4,771,000 after acquiring an additional 5,368 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of iTeos Therapeutics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 640,350 shares of the company's stock worth $6,540,000 after purchasing an additional 20,092 shares during the period. Empowered Funds LLC increased its position in shares of iTeos Therapeutics by 5.0% during the 4th quarter. Empowered Funds LLC now owns 69,072 shares of the company's stock worth $530,000 after purchasing an additional 3,305 shares during the last quarter. Virtu Financial LLC raised its holdings in iTeos Therapeutics by 84.3% in the 4th quarter. Virtu Financial LLC now owns 18,493 shares of the company's stock valued at $142,000 after buying an additional 8,460 shares during the period. Finally, US Bancorp DE lifted its position in iTeos Therapeutics by 40.1% in the fourth quarter. US Bancorp DE now owns 16,919 shares of the company's stock valued at $130,000 after buying an additional 4,843 shares during the last quarter. Institutional investors and hedge funds own 97.16% of the company's stock.

iTeos Therapeutics Trading Down 3.1 %

ITOS traded down $0.21 during trading hours on Wednesday, hitting $6.42. 466,555 shares of the company's stock were exchanged, compared to its average volume of 487,092. The firm has a market cap of $245.53 million, a P/E ratio of -2.04 and a beta of 1.39. iTeos Therapeutics, Inc. has a 12-month low of $4.80 and a 12-month high of $18.75. The firm has a 50 day moving average of $6.58 and a 200 day moving average of $7.49.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14. As a group, research analysts expect that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ITOS has been the topic of a number of research analyst reports. HC Wainwright reissued a "buy" rating and issued a $46.00 price target on shares of iTeos Therapeutics in a research note on Thursday, March 6th. Wedbush reissued an "outperform" rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. JPMorgan Chase & Co. lowered their price target on iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating for the company in a research report on Thursday, March 6th. Finally, Wells Fargo & Company cut their price objective on iTeos Therapeutics from $17.00 to $16.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.